Topcon Healthcare Inc. has acquired RetInSight GmbH, a developer of retinal imaging AI solutions. According to a company news release, the move advances Topcon’s vision of “Healthcare from the Eye,” its connected-care ecosystem using AI-powered disease detection and management applied to noninvasive retinal imaging in order to increase access to quality eye care, improve clinical outcomes and reduce health care costs.

RetInSight’s AI algorithms analyze optical coherence tomography (OCT) images taken in routine clinical care to detect and monitor major retinal diseases, including neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, the press release stated. The result is the possibility of earlier interventions and personalized treatment planning.

RetInSight’s platform is operable across multiple OCT systems and is already used in pharmaceutical trials as well as already commercialized throughout Europe, according to the company.

“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. “This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”